dc.contributor.author | Fendler, A | |
dc.contributor.author | Au, L | |
dc.contributor.author | Shepherd, STC | |
dc.contributor.author | Byrne, F | |
dc.contributor.author | Cerrone, M | |
dc.contributor.author | Boos, LA | |
dc.contributor.author | Rzeniewicz, K | |
dc.contributor.author | Gordon, W | |
dc.contributor.author | Shum, B | |
dc.contributor.author | Gerard, CL | |
dc.contributor.author | Ward, B | |
dc.contributor.author | Xie, W | |
dc.contributor.author | Schmitt, AM | |
dc.contributor.author | Joharatnam-Hogan, N | |
dc.contributor.author | Cornish, GH | |
dc.contributor.author | Pule, M | |
dc.contributor.author | Mekkaoui, L | |
dc.contributor.author | Ng, KW | |
dc.contributor.author | Carlyle, E | |
dc.contributor.author | Edmonds, K | |
dc.contributor.author | Rosario, LD | |
dc.contributor.author | Sarker, S | |
dc.contributor.author | Lingard, K | |
dc.contributor.author | Mangwende, M | |
dc.contributor.author | Holt, L | |
dc.contributor.author | Ahmod, H | |
dc.contributor.author | Stone, R | |
dc.contributor.author | Gomes, C | |
dc.contributor.author | Flynn, HR | |
dc.contributor.author | Agua-Doce, A | |
dc.contributor.author | Hobson, P | |
dc.contributor.author | Caidan, S | |
dc.contributor.author | Howell, M | |
dc.contributor.author | Wu, M | |
dc.contributor.author | Goldstone, R | |
dc.contributor.author | Crawford, M | |
dc.contributor.author | Cubitt, L | |
dc.contributor.author | Patel, H | |
dc.contributor.author | Gavrielides, M | |
dc.contributor.author | Nye, E | |
dc.contributor.author | Snijders, AP | |
dc.contributor.author | MacRae, JI | |
dc.contributor.author | Nicod, J | |
dc.contributor.author | Gronthoud, F | |
dc.contributor.author | Shea, RL | |
dc.contributor.author | Messiou, C | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Chau, I | |
dc.contributor.author | Starling, N | |
dc.contributor.author | Turner, N | |
dc.contributor.author | Welsh, L | |
dc.contributor.author | van As, N | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Droney, J | |
dc.contributor.author | Banerjee, S | |
dc.contributor.author | Tatham, KC | |
dc.contributor.author | Jhanji, S | |
dc.contributor.author | O'Brien, M | |
dc.contributor.author | Curtis, O | |
dc.contributor.author | Harrington, K | |
dc.contributor.author | Bhide, S | |
dc.contributor.author | Bazin, J | |
dc.contributor.author | Robinson, A | |
dc.contributor.author | Stephenson, C | |
dc.contributor.author | Slattery, T | |
dc.contributor.author | Khan, Y | |
dc.contributor.author | Tippu, Z | |
dc.contributor.author | Leslie, I | |
dc.contributor.author | Gennatas, S | |
dc.contributor.author | Okines, A | |
dc.contributor.author | Reid, A | |
dc.contributor.author | Young, K | |
dc.contributor.author | Furness, AJS | |
dc.contributor.author | Pickering, L | |
dc.contributor.author | Gandhi, S | |
dc.contributor.author | Gamblin, S | |
dc.contributor.author | Swanton, C | |
dc.contributor.author | Crick COVID-19 Consortium, | |
dc.contributor.author | Nicholson, E | |
dc.contributor.author | Kumar, S | |
dc.contributor.author | Yousaf, N | |
dc.contributor.author | Wilkinson, KA | |
dc.contributor.author | Swerdlow, A | |
dc.contributor.author | Harvey, R | |
dc.contributor.author | Kassiotis, G | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Wilkinson, RJ | |
dc.contributor.author | Turajlic, S | |
dc.contributor.author | CAPTURE consortium, | |
dc.date.accessioned | 2022-01-17T09:53:59Z | |
dc.date.available | 2022-01-17T09:53:59Z | |
dc.date.issued | 2021-09-20 | |
dc.identifier.citation | Nature Cancer, 2021, 2 (12), pp. 1321 - 1337 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4961 | |
dc.identifier.eissn | 2662-1347 | |
dc.identifier.eissn | 2662-1347 | |
dc.identifier.doi | 10.1038/s43018-021-00275-9 | |
dc.identifier.doi | 10.1038/s43018-021-00275-9 | |
dc.description.abstract | Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer. | |
dc.format.extent | 1321 - 1337 | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | NATURE PORTFOLIO | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-09-17 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1038/s43018-021-00275-9 | |
dc.relation.isPartOf | Nature Cancer | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/ImmNet | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/MD(Res) | |
pubs.organisational-group | /ICR/Students/MD(Res)/Starting Cohort 20/21 | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 2 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (RMH Smith Cunningham) | |
icr.researchteam | Melanoma and Kidney Cancer | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Au, Lewis | |
dc.contributor.icrauthor | Shepherd, Scott | |
dc.contributor.icrauthor | Shum, Ben | |
dc.contributor.icrauthor | Turner, Nicholas | |
dc.contributor.icrauthor | Curtis, Olivia | |
dc.contributor.icrauthor | Harrington, Kevin | |
dc.contributor.icrauthor | Bhide, Shreerang | |
dc.contributor.icrauthor | Furness, Andrew | |